GB2504139B - Antibodies to highly conserved targets produced by the immunisation of Camelidae species - Google Patents

Antibodies to highly conserved targets produced by the immunisation of Camelidae species

Info

Publication number
GB2504139B
GB2504139B GB1212940.9A GB201212940A GB2504139B GB 2504139 B GB2504139 B GB 2504139B GB 201212940 A GB201212940 A GB 201212940A GB 2504139 B GB2504139 B GB 2504139B
Authority
GB
United Kingdom
Prior art keywords
immunisation
antibodies
highly conserved
camelidae species
targets produced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1212940.9A
Other languages
English (en)
Other versions
GB2504139A (en
GB201212940D0 (en
Inventor
Johannes Joseph Wilhelmus De Haard
Christophe Frederic Jerome Blanchetot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX SE
Original Assignee
ArgenX SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX SE filed Critical ArgenX SE
Priority to GB1212940.9A priority Critical patent/GB2504139B/en
Publication of GB201212940D0 publication Critical patent/GB201212940D0/en
Priority to PCT/EP2012/071866 priority patent/WO2013064701A2/en
Priority to IN91DEN2015 priority patent/IN2015DN00091A/en
Priority to US14/415,370 priority patent/US20150191548A1/en
Priority to EP13742418.0A priority patent/EP2875048A2/en
Priority to JP2015522117A priority patent/JP2015524404A/ja
Priority to AU2013291937A priority patent/AU2013291937A1/en
Priority to PCT/EP2013/065350 priority patent/WO2014013075A2/en
Priority to CA2877446A priority patent/CA2877446A1/en
Priority to CN201380038485.7A priority patent/CN104520317A/zh
Publication of GB2504139A publication Critical patent/GB2504139A/en
Priority to IL236525A priority patent/IL236525A0/en
Application granted granted Critical
Publication of GB2504139B publication Critical patent/GB2504139B/en
Priority to US15/718,984 priority patent/US20180016351A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GB1212940.9A 2011-11-03 2012-07-20 Antibodies to highly conserved targets produced by the immunisation of Camelidae species Active GB2504139B (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GB1212940.9A GB2504139B (en) 2012-07-20 2012-07-20 Antibodies to highly conserved targets produced by the immunisation of Camelidae species
PCT/EP2012/071866 WO2013064701A2 (en) 2011-11-03 2012-11-05 Bispecific antibodies and methods for isolating same
AU2013291937A AU2013291937A1 (en) 2012-07-20 2013-07-19 Antibodies to highly conserved targets
CN201380038485.7A CN104520317A (zh) 2012-07-20 2013-07-19 针对高度保守靶标的包含来自骆驼科之序列的抗体
EP13742418.0A EP2875048A2 (en) 2012-07-20 2013-07-19 Antibodies comprising sequences from camelidae to highly conserved targets
JP2015522117A JP2015524404A (ja) 2012-07-20 2013-07-19 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
IN91DEN2015 IN2015DN00091A (https=) 2012-07-20 2013-07-19
PCT/EP2013/065350 WO2014013075A2 (en) 2012-07-20 2013-07-19 Antibodies to highly conserved targets
CA2877446A CA2877446A1 (en) 2012-07-20 2013-07-19 Antibodies comprising sequences from camelidae to highly conserved targets
US14/415,370 US20150191548A1 (en) 2012-07-20 2013-07-19 Antibodies comprising sequences from camelidae to highly conserved targets
IL236525A IL236525A0 (en) 2012-07-20 2014-12-31 Antibodies against conserved targets
US15/718,984 US20180016351A1 (en) 2012-07-20 2017-09-28 Antibodies comprising sequences from camelidae to highly conserved targets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1212940.9A GB2504139B (en) 2012-07-20 2012-07-20 Antibodies to highly conserved targets produced by the immunisation of Camelidae species

Publications (3)

Publication Number Publication Date
GB201212940D0 GB201212940D0 (en) 2012-09-05
GB2504139A GB2504139A (en) 2014-01-22
GB2504139B true GB2504139B (en) 2014-12-31

Family

ID=46881721

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1212940.9A Active GB2504139B (en) 2011-11-03 2012-07-20 Antibodies to highly conserved targets produced by the immunisation of Camelidae species

Country Status (10)

Country Link
US (2) US20150191548A1 (https=)
EP (1) EP2875048A2 (https=)
JP (1) JP2015524404A (https=)
CN (1) CN104520317A (https=)
AU (1) AU2013291937A1 (https=)
CA (1) CA2877446A1 (https=)
GB (1) GB2504139B (https=)
IL (1) IL236525A0 (https=)
IN (1) IN2015DN00091A (https=)
WO (2) WO2013064701A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
GB201414823D0 (en) * 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
CN107613974B (zh) 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
DK3277719T3 (da) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
HK1250011A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 具有蛋白酶可切割接头的肽构建体
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
WO2016156475A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
AU2016261854B2 (en) * 2015-05-12 2022-05-26 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
EP3384030A4 (en) * 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018103093A1 (zh) * 2016-12-09 2018-06-14 深圳华大基因研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
DK3728328T5 (da) 2017-12-22 2025-02-17 Argenx Bvba Bispecifik antigenbindende konstruktion
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
KR20250048558A (ko) * 2022-08-15 2025-04-09 엠브레이스 테라퓨틱스, 인크. 세포내 표적에 대한 항체를 생산하는 무세포 방법
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
CN121219320A (zh) 2023-05-19 2025-12-26 达科纳治疗有限公司 针对il12受体的双特异性激动性抗体
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
WO2026044000A1 (en) 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof
WO2026080748A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026080757A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies
WO2026080752A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. De novo antibodies to activin a receptor like type 1 (alk1)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546A (en) * 2008-07-02 2010-01-06 Argen X Bv Antigen binding polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
JP3683278B2 (ja) * 1995-12-20 2005-08-17 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション マウスモノクローナル抗イディオタイプ抗体１１ｄ１０およびその使用方法
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
US7585504B2 (en) * 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
US8444976B2 (en) * 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
NZ607337A (en) * 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546A (en) * 2008-07-02 2010-01-06 Argen X Bv Antigen binding polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COBALT sequence alignment: GenBank Accession Nos CAG33144, AAI10668, AAI02930, NP_001002937, NP_037095, NP_990233 *
FEBS J; Vol 276, pp 3881-3893 (2009). Behar et al. "Llama single-domain antibodies directed against nonconventional epitopes of tumour-associated carcinoembryonic antigen..." Available online at: http://onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2009.07101.x/pdf *
J Immunol Methods; Vol 263, pp 97-109 (2002). Tanha et al. "Selection by phage display of llama conventional VH fragments with heavy chain antibody VHH properties" *
Proc Natl Acad Sci USA; Vol 103, pp 15130-15135 (2006). Janssens et al. "Generation of heavy-chain-only antibodies in mice". Available online at: http://www.pnas.org/content/103/41/15130.full.pdf *

Also Published As

Publication number Publication date
US20150191548A1 (en) 2015-07-09
WO2013064701A3 (en) 2013-07-18
WO2014013075A3 (en) 2014-12-18
IL236525A0 (en) 2015-02-26
CA2877446A1 (en) 2014-01-23
CN104520317A (zh) 2015-04-15
US20180016351A1 (en) 2018-01-18
GB2504139A (en) 2014-01-22
GB201212940D0 (en) 2012-09-05
IN2015DN00091A (https=) 2015-05-29
AU2013291937A1 (en) 2015-01-22
WO2013064701A2 (en) 2013-05-10
JP2015524404A (ja) 2015-08-24
WO2014013075A2 (en) 2014-01-23
EP2875048A2 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
GB2504139B (en) Antibodies to highly conserved targets produced by the immunisation of Camelidae species
IL289241A (en) Antibodies to tau
IL228001A0 (en) Antibodies to 70cd
EP2862125A4 (en) DEPTH-BASED CONTEXT IDENTIFICATION
SG10201510341XA (en) Antigen-binding molecule inducing immune response to target antigen
EP2855745A4 (en) METHODS RELATING TO ADALIMUM AB
EP2932375A4 (en) ADAPTATION OF OPPORTUNITY IN CONTEXT
GB201315851D0 (en) Antibodies to complex targets
EP2766301A4 (en) DRAINING PHOSPHATE PRECIPITATES
GB201222625D0 (en) Improvements relating to tracking moving objects
PL2797436T3 (pl) Sposoby wytwarzania napojów na bazie roślin
EP2861068A4 (en) METHODS ASSOCIATED WITH BEVACIZUMAB
DK2728009T3 (da) Fremgangsmåde til fremstilling af monosaccharider
PL2918672T3 (pl) Sposób określania wrażliwości drobnoustrojów na substancje przeciwdrobnoustrojowe
PL399418A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A0 (en) Process for the preparation of 5-fluoro-h1-pyrazoles
WO2013168176A3 (en) Process for preparation of fosaprepitant and salt thereof
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
WO2013011062A3 (en) Antagonistic antibodies against oscar
PL2861400T3 (pl) Sposób regulacji temperatury obiektów
EP2852411A4 (en) ANTI-CCL2 ANTIBODIES FOR THE TREATMENT OF SCLEROMERMIA
SI2678015T1 (sl) Uporaba nifuratela za zdravljenje infekcij, povzroäśenih z vrstami clostridium
GB201106003D0 (en) EUISMO or e/is/m/o atmospric engine
AU2012900977A0 (en) Improvements to the manufacture of biochar-coke
UA30597S (uk) Ємність для приготування коктейлів

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20170706 AND 20170715